Center for Data Sciences Archives - Sanford Burnham Prebys
Institute News

Mapping the human body to better treat disease

AuthorGreg Calhoun
Date

August 20, 2024

Scientists build supersized sets of biological data to better treat diseases and reveal the secrets to youth by mapping the body at the single-cell level.

Scientists at Sanford Burnham Prebys are investigating the inner workings of our bodies and the trillions of cells within them at a level of detail that few futurists could have predicted. 

“The scale of the data we can generate and analyze has certainly exploded,” says Yu Xin (Will) Wang, PhD, assistant professor in the Development, Aging and Regeneration Program at Sanford Burnham Prebys. “When I was a graduate student, I would take about a hundred pictures for my experiment and spend weeks manually classifying certain characteristics of the imaged cells.” 

“Now, a single experiment would capture probably hundreds of thousands of images and study the gene and protein expression patterns of millions of individual cells.” 

The Wang lab specializes in advanced spatial multi-omic analyses that capture the location of cells, proteins and other molecules in the body. Wang uses spatial multi-omics to explore how dysfunctional autoimmune responses—when the immune system attacks the body’s own tissues—can interfere with its ability to repair and regenerate. As well as being relevant to disease, autoimmune responses also play a role in “inflammaging,” the low-level, chronic inflammation that occurs with age. Inflammaging is thought to contribute to many of the physical signs of aging.  

“My team thinks about diseases from the perspective of how cells behave in response to changes in the body,” says Wang. “We’re interested in how interactions between the immune and peripheral nervous systems change as people age and make us susceptible to frailty and disease.” 

spectrum of immune cells

A spectrum of immune cells being studied by Will Wang’s lab at Sanford Burnham Prebys. Image courtesy of postdoctoral associate Beatrice Silvestri, PhD.

Yu Xin (Will) Wang, PhD

Yu Xin (Will) Wang, PhD, is an assistant professor in the Development, Aging and Regeneration Program at Sanford Burnham Prebys.

This spatial multi-omics approach is helping scientific teams across the world on projects to understand how the body works at the cellular level. Efforts such as the Human Cell Atlas and the Human BioMolecular Atlas Program seek to develop a cellular map of the human body.  Researchers at Sanford Burnham Prebys are now using these tools to map complex diseases including cancer and degenerative conditions such as muscular dystrophy and ischemic injuries. Wang is also working to map cellular changes in aging through the San Diego Tissue Mapping Center of the Cellular Senescence Network (SenNet), a collaborative effort led by Peter D. Adams, PhD, director of, and professor in, the Institute’s Cancer Genome and Epigenetics Program and Bing Ren, PhD, professor of Cellular and Molecular Medicine at UC San Diego.  

“Integrating multiple types of -omics data can give us a much more comprehensive picture as we study health and disease,” notes Wang. Each additional layer of imaging and sequencing data adds more complexity to how Wang and his peers process and analyze their results. This has driven Wang and his colleagues to develop computational algorithms and AI tools to find patterns and novel translatable targets from these “big data” experiments. 

Wang credits San Diego-based biotechnology company Illumina for playing a major role by creating next-generation sequencing technology that improved the speed and accuracy of genome sequencing. The cost of sequencing steadily declined after Illumina launched the Genome Analyzer platform in 2007, making this research method more accessible to scientists at Sanford Burnham Prebys and around the globe. 

A series of additional technology platforms and research disciplines have followed, allowing scientists to study other parts of biological systems in similarly exhaustive detail. These include epigenomics, transcriptomics, proteomics and metabolomics. Scientists are now able to incorporate more than one of these levels of inquiry into an experiment, which is known as multi-omics.    

Connections in the brain

Connections in the brain photographed during experiments at the Institute.
Image courtesy of postdoctoral associate Sara Ancel, PhD, and Annanya Sethiya, MS, research associate II.

“The amount of information you get back from these sequencing platforms, as well as the application of highly multiplexed biomolecular imaging, has exponentially increased, which really helps us to resolve what we couldn’t before to better understand the genetic regulation of cells and diseases,” says Wang. “The most challenging part is the work to derive the meaning from these massive amounts of information. Thankfully, that’s also the most fun part of what we do.” 


Programming in a Petri Dish, an 8-part series

How artificial intelligence, machine learning and emerging computational technologies are changing biomedical research and the future of health care

  • Part 1 – Using machines to personalize patient care. Artificial intelligence and other computational techniques are aiding scientists and physicians in their quest to prescribe or create treatments for individuals rather than populations.
  • Part 2 – Objective omics. Although the hypothesis is a core concept in science, unbiased omics methods may reduce attachments to incorrect hypotheses that can reduce impartiality and slow progress.
  • Part 3 – Coding clinic. Rapidly evolving computational tools may unlock vast archives of untapped clinical information—and help solve complex challenges confronting health care providers.
  • Part 4 – Scripting their own futures. At Sanford Burnham Prebys Graduate School of Biomedical Sciences, students embrace computational methods to enhance their research careers.
  • Part 5 – Dodging AI and computational biology dangers. Sanford Burnham Prebys scientists say that understanding the potential pitfalls of using AI and other computational tools to guide biomedical research helps maximize benefits while minimizing concerns.
  • Part 6 – Mapping the human body to better treat disease. Scientists synthesize supersized sets of biological and clinical data to make discoveries and find promising treatments.
  • Part 7 – Simulating science or science fiction? By harnessing artificial intelligence and modern computing, scientists are simulating more complex biological, clinical and public health phenomena to accelerate discovery.
  • Part 8 – Acceleration by automation. Increases in the scale and pace of research and drug discovery are being made possible by robotic automation of time-consuming tasks that must be repeated with exhaustive exactness.
Institute News

Dodging AI and other computational biology dangers

AuthorGreg Calhoun
Date

August 13, 2024

Sanford Burnham Prebys scientists say that understanding the potential pitfalls of using artificial intelligence and computational biology techniques in biomedical research helps maximize benefits while minimizing concerns

ChatGPT, an artificial intelligence (AI) “chatbot” that can understand and generate human language, steals most headlines related to AI along with the rising concerns about using AI tools to create false “deepfake” images, audio and video that appear convincingly real.

But scientific applications of AI and other computational biology methods are gaining a greater share of the spotlight as research teams successfully employ these techniques to make new discoveries such as predicting how patients will respond to cancer drugs.

AI and computational biology have proven to be boons to scientists searching for patterns in massive datasets, but some researchers are raising alarms about how AI and other computational tools are developed and used.

“We cannot just purely trust AI,” says Yu Xin (Will) Wang, PhD, assistant professor in the Development, Aging and Regeneration Program at Sanford Burnham Prebys. “You need to understand its limitations, what it’s able to do and what it’s not able to do. Probably one of the simplest examples would be people asking ChatGPT about current events as they happen.”

(ChatGPT has access only to news information up to certain cutoff dates based on the training set of websites and other information used for the most current version. Thus, its awareness of current events is not necessarily current.)

“I see a misconception where some people think that AI is so intelligent that you can just throw data at an AI model and it will figure it all out by itself,” says Andrei Osterman, PhD, vice dean and associate dean of curriculum for the Graduate School of Biomedical Sciences and professor in the Immunity and Pathogenesis Program at Sanford Burnham Prebys.

Yu Xin (Will) Wang, PhD

Yu Xin (Will) Wang, PhD, is an assistant professor in the Development, Aging and Regeneration Program at Sanford Burnham Prebys.

“In many cases, it’s not that simple. We can’t look at these models as black boxes where you put the data in and get an answer out, where you have no idea how the answer was determined, what it means and how it is applicable and generalizable.”

“The very first thing to focus on when properly applying computational methods or AI methods is data quality,” adds Kevin Yip, PhD, professor in the Cancer Genome and Epigenetics Program at Sanford Burnham Prebys and director of the Bioinformatics Shared Resource. “Our mantra is ‘garbage in, garbage out.’”

Andrei Osterman, PhD

Andrei Osterman, PhD, is a professor in the Immunity and Pathogenesis Program at Sanford Burnham Prebys.

Once researchers have ensured the quality of their data, Yip says the next step is to be prepared to confirm the results.

“Once we actually plug into certain tools, how can we actually tell whether they are doing a good job or not?” asks Yip. “We cannot just trust them. We need to have ways to validate either experimentally or even computationally using other ways to cross-check the findings.”

Yip is concerned that AI-based research and computational biology are moving too fast in some cases, contributing to challenges reproducing and generalizing results.

“There are so many new algorithms, so many tools published every day,” adds Yip. “Sometimes, they are not maintained very well, and the investigators cannot be reached when we can’t run their code or download the data they analyzed.”

For AI and computational biology techniques to continue their rapid development, it is important for the scientific community to be responsible, transparent and collaborative in sharing data and either code or trained AI models so that studies can be reproduced to enhance trust as these fields grow.

Privacy is another potential breeding ground for mistrust in research using AI algorithms to analyze medical data, from electronic health records to insurance claims data to biopsied patient samples.

“It is completely understandable that members of the public are concerned about the privacy of their personal data as it is a primary topic I discuss with colleagues at conferences,” says Yip. “When we work with patient data, there are very strict rules and policies that we have to follow.”

Yip adds that the most important rule is for scientists to never re-identify the samples without proper consent, which means using algorithms to predict which patient provided certain data.

Kevin Yip, PhD

Kevin Yip, PhD, is a professor in the Cancer Genome and Epigenetics Program at Sanford Burnham Prebys.

Ultimately for Yip, using AI and computational methods appropriately—within their limitations and without violating patients’ privacy—is a matter of professional integrity for the owners and users of these emerging technologies.

“As creators of AI and computational tools, we need to maintain our code and models and make sure they are accessible along with our data. On the other side, users need to understand the limitations and how to make good use of what we create without overstepping and claiming findings beyond the capability of the tools.”

 “This level of shared responsibility is very important for the future of biomedical research during the data revolution.”


Programming in a Petri Dish, an 8-part series

How artificial intelligence, machine learning and emerging computational technologies are changing biomedical research and the future of health care

  • Part 1 – Using machines to personalize patient care. Artificial intelligence and other computational techniques are aiding scientists and physicians in their quest to prescribe or create treatments for individuals rather than populations.
  • Part 2 – Objective omics. Although the hypothesis is a core concept in science, unbiased omics methods may reduce attachments to incorrect hypotheses that can reduce impartiality and slow progress.
  • Part 3 – Coding clinic. Rapidly evolving computational tools may unlock vast archives of untapped clinical information—and help solve complex challenges confronting health care providers.
  • Part 4 – Scripting their own futures. At Sanford Burnham Prebys Graduate School of Biomedical Sciences, students embrace computational methods to enhance their research careers.
  • Part 5 – Dodging AI and computational biology dangers. Sanford Burnham Prebys scientists say that understanding the potential pitfalls of using AI and other computational tools to guide biomedical research helps maximize benefits while minimizing concerns.
  • Part 6 – Mapping the human body to better treat disease. Scientists synthesize supersized sets of biological and clinical data to make discoveries and find promising treatments.
  • Part 7 – Simulating science or science fiction? By harnessing artificial intelligence and modern computing, scientists are simulating more complex biological, clinical and public health phenomena to accelerate discovery.
  • Part 8 – Acceleration by automation. Increases in the scale and pace of research and drug discovery are being made possible by robotic automation of time-consuming tasks that must be repeated with exhaustive exactness.
Institute News

Using machines to personalize patient care

AuthorGreg Calhoun
Date

July 30, 2024

Artificial intelligence (AI) and other computational techniques are aiding scientists and physicians in their quest to create treatments for individuals rather than populations

The Human Genome Project captured the public’s imagination with its global quest to better understand the genetic blueprint stored on the DNA within our cells. The project succeeded in delivering the first-ever sequence of the human genome while foreshadowing a future for medicine once considered to be science fiction. The project presaged the possibility that health care could be personalized based on clues within a patient’s unique genetic code.

Chavez lab

The Chavez Lab

While many more people have undergone genetic testing through consumer genealogy and health services such as 23andMe and Ancestry than through health care systems, genomic sequencing has influenced clinical care in some specialties. Personalized medicine—also known as precision medicine or genomic medicine—has been especially helpful for people suffering from rare diseases that historically have been difficult to diagnose and treat.

Scientists at Sanford Burnham Prebys are employing new technologies and expertise to test ways to improve diagnoses and customize treatments for many diseases based on unique characteristics within tumors, blood samples and other biopsies.

AI and other computational techniques are enabling patient samples to be rapidly analyzed and compared to data from vast numbers of individuals who have been treated for the same condition. Physicians can use AI and other tools to identify subtypes of cancers and other conditions, as well as improve selection of eligible candidates for clinical trials.

“I think we’ve gotten a lot better at precision diagnostics,” says Lukas Chavez, PhD, an assistant professor in the Cancer Genome and Epigenetics Program at Sanford Burnham Prebys. “In my work at Rady Children’s Hospital in cancer, we can characterize a tumor based on mutations, including predicting how quickly different tumors will spread. What we too often lack, however, are better treatment approaches or medicines. That will be the next generation of precision medicine.”

Sanju Sinha, PhD, an assistant professor in the Cancer Molecular Therapeutics Program at Sanford Burnham Prebys, is developing projects to help bridge the gap between precision diagnostics and treatment. He is partnering with the National Cancer Institute on a first-of-its-kind computational tool to systematically predict patient response to cancer drugs at single-cell resolution.

A study published in the journal  Nature Cancer discussed how the tool, called PERCEPTION, was successfully validated by predicting the response to individual therapies and combination treatments in three independent published clinical trials for multiple myeloma, breast and lung cancer.

Lukas Chavez, PhD

Lukas Chavez, PhD, is an assistant professor in the Cancer Genome and Epigenetics Program at Sanford Burnham Prebys.

In each case, PERCEPTION correctly stratified patients into responder and non-responder categories. In lung cancer, it even captured the development of drug resistance as the disease progressed, a notable discovery with great potential.

Sanju Sinha, PhD

Sanju Sinha, PhD, is an assistant professor in the Cancer Molecular
Therapeutics Program at Sanford Burnham Prebys.

“The ability to monitor the emergence of resistance is the most exciting part for me,” says Sinha. “It has the potential to allow us to adapt to the evolution of cancer cells and even modify our treatment strategy.”

While PERCEPTION is not yet ready for clinics, Sinha hopes that widespread adoption of this technology will generate more data, which can be used to further develop and refine the technology for use by health care providers.

In another project, Sinha is focused on patients being treated for potential cancers that may never progress into dangerous conditions warranting treatment and its accompanying side effects.

“Many women who are diagnosed with precancerous changes in the breast seek early treatment,” says Sinha. “Most precancerous cells never lead to cancer, so it may be that as many as eight of 10 women with this diagnosis are being overtreated, which is a huge issue.”

To try and counter this phenomenon, Sinha is training AI models on images of biopsied samples in conjunction with multi-omics sequencing data. His team’s goal is to develop a tool capable of predicting which patients’ cancers would progress based on the imaged samples alone.

“In the field of precancer, insurance does not cover the cost of computing this omics data,” says Sinha. “Health care systems do routinely generate histopathological slides from patient biopsies, so we feel that a tool leveraging these images could be a scalable and accessible solution.”

If Sinha’s team is successful, an AI tool integrated into clinics would predict whether precancerous cells would progress within the next 10 years to guide treatment decisions and how patients are monitored.

“With precision medicine, our hope is not to just treat patients with better drugs, but also to make sure that patients are not unnecessarily treated and made to bear needless costs and side effects that disrupt their quality of life.”


Programming in a Petri Dish, an 8-part series

How artificial intelligence, machine learning and emerging computational technologies are changing biomedical research and the future of health care

  • Part 1 – Using machines to personalize patient care. Artificial intelligence and other computational techniques are aiding scientists and physicians in their quest to prescribe or create treatments for individuals rather than populations.
  • Part 2 – Objective omics. Although the hypothesis is a core concept in science, unbiased omics methods may reduce attachments to incorrect hypotheses that can reduce impartiality and slow progress.
  • Part 3 – Coding clinic. Rapidly evolving computational tools may unlock vast archives of untapped clinical information—and help solve complex challenges confronting health care providers.
  • Part 4 – Scripting their own futures. At Sanford Burnham Prebys Graduate School of Biomedical Sciences, students embrace computational methods to enhance their research careers.
  • Part 5 – Dodging AI and computational biology dangers. Sanford Burnham Prebys scientists say that understanding the potential pitfalls of using AI and other computational tools to guide biomedical research helps maximize benefits while minimizing concerns.
  • Part 6 – Mapping the human body to better treat disease. Scientists synthesize supersized sets of biological and clinical data to make discoveries and find promising treatments.
  • Part 7 – Simulating science or science fiction? By harnessing artificial intelligence and modern computing, scientists are simulating more complex biological, clinical and public health phenomena to accelerate discovery.
  • Part 8 – Acceleration by automation. Increases in the scale and pace of research and drug discovery are being made possible by robotic automation of time-consuming tasks that must be repeated with exhaustive exactness.